Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program.

Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program.

<h4>Background</h4>Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated for the treatment of solid tumors. This publication describes the safety profile of onartuzumab in patients wi...

Full description

Bibliographic Details
Main Authors: Roland Morley, Alison Cardenas, Peter Hawkins, Yasuyo Suzuki, Virginia Paton, See-Chun Phan, Mark Merchant, Jessie Hsu, Wei Yu, Qi Xia, Daniel Koralek, Patricia Luhn, Wassim Aldairy
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0139679

Internet

https://doi.org/10.1371/journal.pone.0139679

Similar Items